NCT01591343 - Safety Study of Depigoid Vaccine Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml), to Treat Allergic Rhinitis or Rhinoconjunctivitis With or Without Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Allergic RhinitisRhinoconjunctivitisMild Persistent AsthmaMild Intermittent Asthma

Interventions

BIOLOGICAL

Depigoid® (500 DPP/ml)

"Depigoid® D. pteronyssinus or Depigoid® 50% D. pteronyssinus / 50% D. farinae (500 DPP/ml).~Dose:~Week 0: 0.2 ml followed by 0.3 ml after 30 min Week 4, 8, 12, and 16: 0.5 ml Mode of administration: subcutaneous injection"

Trial Locations (10)

11008

Clínica Doctor Lobatón, Cadiz

35010

Hospita Universitario Dr. Negrín, Las Palmas de Gran Canaria

39008

Hospital Universitario Marqués de Valdecilla, Santander

43007

Hospital Universitario Joan XXIII, Tarragona

04009

Complejo Hospitalario Torrecárdenas, Almería

08021

Al·lergo Centre, Barcelona

08022

Centro Médico Teknon, Barcelona

08035

Hospital Universitario Vall d'Hebrón, Barcelona

08907

Hospital Universitario de Bellvitge, Barcelona

03020

Complejo Hospitalario Universitario de Cartagena, Cartagena